Articles On Compumedics (ASX:CMP)

Aussie small cap index falls 1.4% The ASX200 down 1.65% Thursday is Arafura Day!   Down less than 2% and I think we can call that a win. No one likes the sight of blood and after the major Wall Street indices shed more than 3.5% a piece,...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

The share price in software company Data#3 Limited (ASX:DTL) has risen around ~12% in morning trade to $6.50 after it said its FY22 results are expected to be better than forecast. Profit up Net profit before tax (NPBT) for the first half...

The ASX edged higher in a fairly directionless session in Thursday trade, after US markets comfortably digested the latest round of inflation data overnight. The iron ore majors led the way with strong demand across the board, with more mut...

Immuron nabs $6.2m clinical research deal for US Military strength Travelan dose ECS Botanics reports record revenue of $1.5m expected for Q2 FY22 Compumedics secures first major magnetoencephalography (MEG) sale in China Immuron (ASX:IMC...

Compumedics has begun the new calendar year with strong sales growth up 33% from the same period last year and a second MEG sale to Tianjin Normal University in China to the tune of $4.2 million.

US markets were more buoyant overnight, after Federal Reserve Chairman Jerome Powell provided some extra context around the bank’s policy tightening plans. In testimony to Congress, Powell reiterated the Fed will end its asset purchase prog...

It was a lacklustre session for local stocks in Tuesday trade, as the ASX 200 limped into the close with a fall of 0.77% while the microcap Emerging Companies index traded flat. In an environment of rising bond yields, the broader tone is s...

Local stocks made a cautious start to the week, following a fairly volatile trading period last week as jitters stemming from rising bond yields dimmed risk sentiment on global markets. The ASX 200 opened in the red before clawing back some...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

The company continues to actively pursue step-out commercial growth opportunities for the MEG and Somfit technology platforms.

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Summary Logistic problems have impacted the revenue pipeline of the company. Compumedics continues to pursue potential sales opportunities in the US market. Compumedics Limited (ASX:CMP) released a business update on Wednesday. The...

Last week in our discussion with Bourse Communication founder and Managing Director Rod North, we examined how COVID-19 compared to other great market impacting events such as the 1987 crash the recession we had to have. This week, we look...

In just two years, skin regenerator Avita Medical (ASX:AVH) has shot up from 6c to 40c and was granted entry into the ASX 200, but the company says it hasn’t made it yet. Chief financial officer David McIntyre, who joined Avita in November...

The Compumedics Limited (ASX: CMP) share price will be one to watch this morning following the release of the medical device company’s half year results. How did Compumedics perform in the first half? During the six months ended December 3...

At time of writing, the share price of Compumedics Ltd [ASX:CMP] is up a significant 25.47% on important FDA approval. It’s been a remarkable 12 months for the stock, with the Compumedics share price rising a total of 154% during this perio...

Another ASX small cap has won the blessing of the Food and Drug Administration (FDA) for its products enter the US market. This morning it was Compumedics (ASX:CMP). Its signature product, the Orion LifeSpan Magnetoencephalography single De...

Compumedics (ASX: CMP) has collared US Food and Drug Administration approval for its neuroimaging technology, enabling insurers to be billed for the scan. On Friday, the FDA officially granted 510(K) clearance to Compumedics for its Orion L...

The Compumedics Limited (ASX: CMP) share price has started the week with a bang. In morning trade the medical device company’s shares rocketed a massive 26% higher to 87.5 cents. Why is the Compumedics share price rocketing higher today? I...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Asia is rising as a healthcare spender, matching incomes and the long-feared elderly population boom. The region is a major part of a surge in health spending that is expected over the next few years, as rising lifestyle illnesses and ages...

In afternoon trade the S&P/ASX 200 index is on course to start the week on a disappointing note. At the time of writing the benchmark index is down 0.45% to 6,896.8 1 points. Four shares that are falling more than most today are listed...

No one likes to hear of a revenue downgrade and shareholders of sleep and brain disorder medical device manufacturer Compumedics (ASX:CMP) are no different. While the company’s earnings guidance for the full year was still $6.5m-$7.5m, unau...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

The Compumedics Limited (ASX: CMP) share price is crashing lower on Monday. At the time of writing the medical device company’s shares are down 22% to 61 cents. Why is the Compumedics shares price sinking lower? Investors have been selling...

In 2019 the culmination of decades worth of work turned several biotechs and life sciences companies into overnight successes. As investors look to defensive growth stocks to compensate for a sluggish economy and with expectations of more h...